Fabasoft AG

  • WKN: 922985
  • ISIN: AT0000785407
  • Land: Österreich

Nachricht vom 28.05.2015 | 21:30

Fabasoft AG announces Group figures for the fiscal year 2014/2015


Fabasoft AG  / Key word(s): Final Results

28.05.2015 21:30

Dissemination of an Ad hoc announcement, transmitted by DGAP - a service of
EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Fabasoft AG (ISIN AT0000785407, WKN 922985, Prime Standard) announces Group figures for the fiscal year 2014/2015 (1 April 2014 - 31 March 2015): - Sales revenue: EUR 27.6 million (EUR 25.0 million in the fiscal year 2013/2014) - EBITDA: EUR 4.6 million (EUR 3.7 million in the fiscal year 2013/2014) - EBIT: EUR 3.0 million (EUR 2.1 million in the fiscal year 2013/2014) - Cash flows from operating activities: EUR 4.6 million (EUR 1.0 million in the fiscal year 2013/2014) - Cash and cash equivalents: EUR 14.6 million as of 31 March 2015 (EUR 13.3 million as of 31 March 2014) At the Annual General Meeting of Fabasoft AG to be held on 6 July 2015 a dividend payment of EUR 0.45 per share will be proposed for the fiscal year 2014/2015 (fiscal year 2013/2014 EUR 0.42 per share). Fabasoft is a leading European software manufacturer and cloud provider. Fabasoft's software products and cloud services ensure the consistent capture, organisation, secure storage and context-sensitive finding of all digital business documents (www.fabasoft.com). Fabasoft AG (ISIN AT0000785407; WKN 922985; Bloomberg Code FAA GY; Reuters Code FAAS.DE) Linz, 28 May 2015 Leopold Bauernfeind, Member of the Managing Board E-mail: Leopold.Bauernfeind@fabasoft.com, Telephone: +43 732 60 61 62 28.05.2015 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English Company: Fabasoft AG Honauerstraße 4 4020 Linz Austria Phone: +43 732-606162-0 Fax: +43 732-606162-609 E-mail: leopold.bauernfeind@fabasoft.com Internet: www.fabasoft.com ISIN: AT0000785407 WKN: 922985 Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Stuttgart, München, Hamburg, Düsseldorf End of Announcement DGAP News-Service

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Vonovia SE: Vorstandsmitglieder von Vonovia werden ihre Bezugsrechte ausüben

30. November 2021, 16:02

Aktueller Webcast

HelloFresh SE

Capital Markets Day

08. Dezember 2021

Aktuelle Research-Studie

clearvise AG

Original-Research: clearvise AG (von First Berlin Equity Research GmbH): Buy

30. November 2021